2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
2
Withdrawn
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Conditions
Neoplasms
15
Pain
13
Pain, Postoperative
12
Depression
9
Breast Neoplasms
9
Agnosia
9
Head and Neck Neoplasms
6
Anxiety Disorders
6
Chronic Pain
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Acute Pain
4
Pancreatic Neoplasms
3
Pain, Intractable
3
Lymphoma, Follicular
3
Colorectal Neoplasms
3
Prostatic Neoplasms
2
Mucositis
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Cancer Pain
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Stomatitis
1
Spinal Stenosis
1
Sezary Syndrome
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Analgesia
1
Polycythemia Vera
1
Interventions
resiniferatoxin
3
Ketamine
3
Morphine
2
Methadone
2
Dexmedetomidine
2
ziconotide
1
substance P-saporin
1
Standard of Care
1
Sodium Chloride
1
Ropivacaine
1
Registries
1
Pregabalin
1
Passive Cutaneous Anaphylaxis
1
Midazolam
1
Lidocaine
1
Infusion Pumps, Implantable
1
Hydromorphone
1
Fentanyl
1
Calcium Dobesilate
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Pain, Intractable
×
Ketamine
×
Clear all
NCT01951911
2017-07-11
KETA-1
Haukeland University Hospital
Phase 3
Withdrawn
NCT01326325
2013-08-07
KEPAL
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
24 enrolled
NCT00484484
2011-05-04
KETADOL
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
100 enrolled